Leerink Swann assumed coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research note published on Friday, January 5th, MarketBeat reports. The firm issued an outperform rating and a $2.00 target price on the biopharmaceutical company’s stock.
RGLS has been the topic of several other reports. Needham & Company LLC restated a hold rating on shares of Regulus Therapeutics in a report on Tuesday, November 14th. Zacks Investment Research downgraded Regulus Therapeutics from a buy rating to a hold rating in a report on Tuesday, September 19th. Finally, Wedbush reiterated an outperform rating and issued a $4.00 price target on shares of Regulus Therapeutics in a report on Monday, December 11th. One analyst has rated the stock with a sell rating, five have issued a hold rating and four have assigned a buy rating to the stock. Regulus Therapeutics has a consensus rating of Hold and an average target price of $2.46.
Shares of Regulus Therapeutics (RGLS) opened at $1.23 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.77 and a current ratio of 6.77. The company has a market capitalization of $127.86, a PE ratio of -0.91 and a beta of 1.55. Regulus Therapeutics has a 52-week low of $0.79 and a 52-week high of $2.60.
A number of hedge funds have recently made changes to their positions in RGLS. Quantitative Investment Management LLC acquired a new position in Regulus Therapeutics during the 2nd quarter worth $103,000. GSA Capital Partners LLP acquired a new position in Regulus Therapeutics during the 2nd quarter worth $139,000. Royal Bank of Canada lifted its holdings in shares of Regulus Therapeutics by 12.1% in the second quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after buying an additional 19,934 shares during the period. Victory Capital Management Inc. acquired a new stake in shares of Regulus Therapeutics in the third quarter valued at $347,000. Finally, Goldman Sachs Group Inc. lifted its holdings in shares of Regulus Therapeutics by 189.1% in the second quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after buying an additional 240,890 shares during the period. Institutional investors own 59.39% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Regulus Therapeutics (NASDAQ:RGLS) Now Covered by Leerink Swann” was originally posted by BBNS and is owned by of BBNS. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://baseballnewssource.com/markets/leerink-swann-initiates-coverage-on-regulus-therapeutics-rgls/1819936.html.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.